SecurityCRK / Comstock Resources, Inc. (205768203)
Chairman & CEOALLISON M JAY
IndustryCrude Petroleum and Natural Gas
Institutional Owners74
Institutional Shares7,581,701 - 46.88%
Common Shares Outstanding16,172,505 shares (as of 2018-03-31)
Institutional Value$ 56,115,000 USD
Related 205768AG9 / Comstock Res Inc Gtdsr Nt8.375% 10/15/17
205768AH7 / Comstock Resources Inc. 7.25% 04/01/19
205768AJ3 / Comstock Resources Inc 9.50% 06/15/20
205768AN4 / Comstock Resources, Inc. Bond
205768AM6 / Comstock Resources, Inc. Bond

Institutional Stock Ownership and Shareholders

CRK / Comstock Resources, Inc. Institutional Ownership

Comstock Resources, Inc. (NYSE:CRK) has 74 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7,581,701 shares. Largest shareholders include Hodges Capital Management Inc., Renaissance Technologies LLC, Vanguard Group Inc, BlackRock Inc., First Washington CORP, Southpaw Asset Management LP, BlackRock Institutional Trust Company, N.A., PointState Capital LP, Millennium Management Llc, and Susquehanna International Group, Llp.
Comstock Resources, Inc. (NYSE:CRK) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/crk"><img src="https://images.fintel.io/us-crk-so.png" alt="CRK / Comstock Resources, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR Walleye Trading LLC 0 10,200 0 75
2018-05-14 13F-HR Renaissance Technologies LLC 145,200 655,500 351.45 1,228 4,792 290.23
2018-05-08 13F-HR Dorsey & Whitney Trust CO LLC 11,510 11,510 0.00 97 84 -13.40
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 3,171 493 -84.45 27 4 -85.19
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 109,510 138,100 26.11 926 1,010 9.07
2018-04-24 13F-HR Parkwood LLC 105,748 0 -100.00 895 0 -100.00
2018-05-10 13F-HR JP Morgan Chase & Co 80,200 0 -100.00 678 0 -100.00
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 99,520 99,520 0.00 842 727 -13.66
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 1,205 1,248 3.57 10 9 -10.00
2018-05-15 13F-HR Bank of New York Mellon Corp 0 11,333 0 83
2018-05-15 13F-HR Paloma Partners Management Co 32,314 0 -100.00 273 0 -100.00
2018-04-13 13F-HR BANK OF MONTREAL /CAN/ 1 22,301 2,230,000.00 0 163
2018-05-01 13F-HR Prime Capital Investment Advisors, Llc 36,340 53,960 48.49 307 394 28.34
2018-05-14 13F-HR BOOTHBAY FUND MANAGEMENT, LLC 56,712 59,072 4.16 480 432 -10.00
2018-05-03 13F-HR Trexquant Investment LP 32,207 235
2018-05-15 13F-HR GUGGENHEIM CAPITAL LLC 263,131 0 -100.00 2,223 0 -100.00
2018-04-13 13F-HR BANK OF MONTREAL /CAN/ Put 22,300 163
2018-05-15 13F-HR BARCLAYS PLC Put 0 500 0 4
2018-05-09 13F-HR Lee Financial CORP 1,040 1,040 0.00 9 8 -11.11
2018-05-09 13F-HR BlackRock Inc. 376,432 373,750 -0.71 3,185 2,733 -14.19
2018-05-09 13F-HR Alpine Investment Management, LLC 50,000 50,000 0.00 423 366 -13.48
2018-05-15 13F-HR WOLVERINE TRADING, LLC 24,517 31,705 29.32 207 232 12.08
2018-05-15 13F-HR/A Graham Capital Management, L.P. 18,669 18,669 0.00 158 136 -13.92
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 99,800 94,900 -4.91 844 694 -17.77
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC Put 0 1,100 0 8
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 178,300 169,600 -4.88 1,508 1,240 -17.77
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. 96,808 38,914 -59.80 819 284 -65.32
2018-05-03 13F-HR Texas Yale Capital Corp. 50,000 50,000 0.00 423 366 -13.48
2018-05-15 13F-HR Squarepoint Ops LLC 18,846 138
2017-01-31 SC 13G/A FIRST TRUST PORTFOLIOS LP 2,808,845 13,722 -99.51
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 171,954 266,299 54.87 1,455 1,947 33.81
2018-05-11 13F-HR Cutler Group LP Call 5,000 1,100 -78.00 12 0 -100.00
2018-05-10 13F-HR Stratos Wealth Partners, LTD. 3,000 22
2018-05-15 13F-HR UBS Group AG 700 48,915 6,887.86 6 358 5,866.67
2018-05-11 13F-HR SYMPHONY ASSET MANAGEMENT LLC 35,750 0 -100.00 302 0 -100.00
2018-05-15 13F-HR TWO SIGMA INVESTMENTS LLC 0 49,557 0 362
2018-05-15 13F-HR BARCLAYS PLC 91,089 82,111 -9.86 771 600 -22.18
2018-05-11 13F-HR Russell Investments Group, Ltd. 64,305 108,677 69.00 513 795 54.97
2018-05-10 13F-HR Spark Investment Management LLC 0 55,900 0 408
2018-05-15 13F-HR WOLVERINE TRADING, LLC Put 22,800 49,800 118.42 193 364 88.60
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 6,001 1,100 -81.67 51 8 -84.31
2018-05-17 13F-HR Atlantic Trust Group, LLC 3,071 22
2018-05-11 13F-HR Delpha Capital Management, Llc 375 0 -100.00 3 0 -100.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 344,809 344,809 0.00 2,634 3,396 28.93
2018-05-15 13F-HR A.R.T. Advisors, LLC 0 31,562 0 230
2018-05-15 13F-HR PointState Capital LP 1,207,702 343,758 -71.54 10,217 2,513 -75.40
2018-05-15 13F-HR HAWK RIDGE CAPITAL MANAGEMENT LP 95,287 697
2018-05-15 13F-HR LASRY MARC 215,250 215,250 0.00 1,821 1,573 -13.62
2018-04-26 13F-HR SIMPLEX TRADING, LLC Call 374 146 -60.96 149 47 -68.46
2018-05-11 13F-HR Quantbot Technologies LP 0 14,320 0 104
2018-05-14 13F-HR MORGAN STANLEY 22,049 74,369 237.29 186 543 191.94
2018-05-15 13F-HR CONTRARIAN CAPITAL MANAGEMENT, L.L.C. 157,016 138,490 -11.80 1,328 1,012 -23.80
2018-05-15 13F-HR Parallax Volatility Advisers, L.P. Call 50,000 0 -100.00 423 0 -100.00
2018-05-03 13F-HR Hodges Capital Management Inc. 1,209,700 1,392,159 15.08 10,234 10,177 -0.56
2018-05-15 13F-HR Invesco Ltd. 128,674 78,503 -38.99 1,089 575 -47.20
2018-04-26 13F-HR SIMPLEX TRADING, LLC Put 204 207 1.47 3 5 66.67
2018-05-15 13F-HR PEAK6 Investments, L.P. 12,345 24,059 94.89 104 176 69.23
2017-02-10 13F-HR BlackRock Fund Advisors 7,515 12,674 68.65 57 125 119.30
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Put 39,000 46,600 19.49 330 341 3.33
2018-05-15 13F-HR Advisor Group, Inc. 200 200 0.00 2 1 -50.00
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 0 291,321 0 2,130
2017-01-13 13F-HR MetLife Securities, Inc 202 802 297.03 2 8 300.00
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 44,516 0 -100.00 377 0 -100.00
2018-05-15 13F-HR VANGUARD GROUP INC 677,678 558,198 -17.63 5,734 4,081 -28.83
2018-04-26 13F-HR SIMPLEX TRADING, LLC 29,349 29,265 -0.29 248 213 -14.11
2018-05-15 13F-HR JANE STREET GROUP, LLC Call 117,000 0 -100.00 990 0 -100.00
2018-05-15 13F-HR ELLINGTON MANAGEMENT GROUP LLC 0 95,700 0 700
2018-05-14 13F-HR Virtu Financial LLC 58,828 22,572 -61.63 498 165 -66.87
2018-05-15 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC 0 2,683 0 20
2018-05-11 13F-HR GSA CAPITAL PARTNERS LLP 129,066 0 -100.00 1,092 0 -100.00
2018-06-14 13F-HR/A Dynamic Technology Lab Private Ltd 50,823 372
2018-05-04 13F-HR First Dallas Securities Inc. 52,909 44,806 -15.31 448 327 -27.01
2018-05-07 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 10,160 10,160 0.00 86 75 -12.79
2018-05-08 13F-HR Alambic Investment Management, L.P. 12,074 88
2018-05-11 13F-HR Cutler Group LP 0 800 0 5
2018-05-15 13F-HR JANE STREET GROUP, LLC 115,717 0 -100.00 979 0 -100.00
2018-05-15 13F-HR BARCLAYS PLC Call 400 0 -100.00 3 0 -100.00
2017-02-14 SC 13G/A D. E. SHAW & CO, L.P. 2,828,292 16,748 -99.41
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 83,927 83,979 0.06 710 613 -13.66
2018-05-15 13F-HR Southpaw Asset Management LP 357,307 357,307 0.00 3,023 2,612 -13.60
2018-04-12 13F-HR ACADIAN ASSET MANAGEMENT LLC 0 12,202 0 89
2018-05-14 13F-HR FULLER & THALER ASSET MANAGEMENT, INC. 26,954 265,700 885.75 228 1,942 751.75
2018-05-15 13F-HR D. E. Shaw & Co., Inc. 50,034 0 -100.00 423 0 -100.00
2018-05-15 13F-HR DEUTSCHE BANK AG\ 300 6,327 2,009.00 2 45 2,150.00
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 153 40 -73.86 1 0 -100.00
2018-05-09 13F-HR NORTHERN TRUST CORP 33,274 46,839 40.77 281 342 21.71
2018-05-09 13F-HR IFP Advisors, Inc 9 9 0.00 0 0
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Call 13,600 8,800 -35.29 115 64 -44.35
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 130 796 512.31 1 6 500.00
2017-02-10 13F-HR BlackRock Advisors LLC 2,950 2,950 0.00 23 29 26.09
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 59,800 0 -100.00 506 0 -100.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 881 881 0.00 7 6 -14.29
2018-05-11 13F-HR MACQUARIE GROUP LTD 12,600 29,000 130.16 107 212 98.13
2018-05-11 13F-HR PENN CAPITAL MANAGEMENT CO INC 15,091 15,091 0.00 128 110 -14.06
2018-05-03 13F-HR QCI ASSET MANAGEMENT INC/NY 735 735 0.00 6 5 -16.67
2018-05-09 13F-HR MESSNER & SMITH THEME VALUE INVESTMENT MANAGEMENT LTD /CA/ 1 1 0.00 0 0
2018-05-15 13F-HR OXFORD ASSET MANAGEMENT 16,230 119
2018-05-15 13F-HR WOLVERINE TRADING, LLC Call 42,700 25,300 -40.75 361 185 -48.75
2018-05-04 13F-HR First Washington CORP 368,562 361,902 -1.81 3,118 2,646 -15.14

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

6 Winning Stock Strategies as Tariff Talks Take Ugly Turn

23h zacks
Wall Street is likely to walk a tightrope with a trade war knocking at the door. This is especially true as tariff talks between the two world’s biggest economies have worsened with Trump threatening to impose additional massive tariffs on Chinese goods unless Beijing reverses course on its own trade actions and does not change its unfair practices. This time, Trump is seeking a tariff on an additional $400 billion worth of Chinese goods on top of the $50 billion already announced on Jun 15. (18-0)

Comstock Resources Eyes Enduro Resource Assets, Places Bid

2018-06-11 zacks
Comstock Resources, Inc. (CRK - Free Report) , according to recent reports, has placed its bid for the Cotton Valley and Haynesville Shale assets of bankrupt Enduro Resource Partners LLC, an exploration and production company that is liquidating its properties. Founded in 2010 and backed by the private equity firm, Riverstone Holdings, Enduro Resource was hit by low oil price environment that shook the industry a few years back. (73-0)

Who's Really Getting Paid in the Oil Sector - Bloomberg

2018-06-09 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (7-0)

Natural Gas Gains After Smaller-than-Average Supply Increase

2018-06-08 zacks
Natural gas prices gained after the U.S. Energy Department's weekly inventory release showed a smaller-than-average increase in supplies. (206-2)

Why You Should Hold Comstock Resources Now

2018-06-06 zacks
We issued an updated research report on Comstock Resources, Inc. (CRK - Free Report) on Jun 4. The company’s major position in the prolific Haynesville/Bossier Shale play provides a highly visible and cost-effective production growth profile. However, the stock’s low liquidity and high leverage are matters of concern. (44-0)

CUSIP: 205768203